An update on depression in children and adolescents

Journal of Clinical Psychiatry

Volumn 69, Issue 11, 2008, Pages 1818-1828

  Wagner, Karen D ^a   Emslie, Graham J ^b   Kowatch, Robert A ^c   Weller, Elizabeth B ^d  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADOLESCENT; BEHAVIOR THERAPY; CHILD; CHILD PSYCHIATRY; CLINICAL FEATURE; COGNITIVE THERAPY; DIFFERENTIAL DIAGNOSIS; DRUG INDICATION; DRUG SAFETY; ETHNIC DIFFERENCE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MENTAL STRESS; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREGNANCY; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK FACTOR; SUICIDE;

EID: 57349139951     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1118     Document Type: Review

References (91)

1. National Alliance on Mental Illness. Depression in children and adolescents. 2003. Available at: www.nami.org/ Template.cfm?Section= by_illness&template=/ContentManagement/ ContentDisplay.cfm&ContentID= 17623. Accessed Oct 9, 2008
2. Stein REK, Zitner LE, Jensen PS. Interventions for adolescent depression in primary care. Pediatrics 2006;118:669-682
3. Schulterbrandt JG, Raskin A. Depression in Childhood: Diagnosis, Treatment and Conceptual Models. New York, NY: Raven Press; 1977
4. Lewinsohn PM, Roberts RE, Seeley JR, et al. Adolescent psychopathology 2: psychosocial risk factors for depression. J Abnorm Psychol 1994;103:302-315
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
6. Klerman GL, Lavori PW, Rice J, et al. Birth-cohort trends in rates of major depressive disorder among relatives of patients with affective disorder. Arch Gen Psychiatry 1985;42:689-693
7. Son SE, Kirchner JT. Depression in children and adolescents. Am Fam Physician 2000;62:2297-2308
8. Angold A, Costello EJ, Worthman CM. Puberty and depression: the roles of age, pubertal status and pubertal timing. Psychol Med 1998;28:51-61
9. Weller EB, Weller RA, Danielyan AK. Mood disorders in prepubertal children. In: Wiener JM, Dulcan MK, eds. Textbook of Child and Adolescent Psychiatry. Washington, DC: American Psychiatric Publishing; 2004:411-435
10. National Institute of Mental Health. Women and Depression. 2007. Available at: www.psychcentral.com/ lib/2007/women-and-depression/. Accessed Sep 7, 2008
11. Frank E, Young E. Pubertal changes and adolescent challenges. In: Frank E, ed. Gender and Its Effect on Psychopathology. Washington, DC: American Psychiatric Press; 2000:85-102
12. Hankin BL, Abramson LY. Development of gender differences in depression: an elaborated cognitive vulnerability-transactional stress theory. Psychol Bull 2001;127:773-796
13. Sands T, Howard-Hamilton M. Understanding depression among gifted adolescent females: feminist theory strategies. Roeper Review 1995;17:192-196
14. Hankin BL, Abramson LY. Development of gender differences in depression: description and possible explanations. Ann Med 1999;31:372-379
15. Waldinger RJ. Mood disorders. In: Waldinger RJ, ed. Psychiatry for Medical Students. 3rd ed. Washington, DC: American Psychiatric Press; 1997:101-141
16. Weller EB. Mood disorders in children and adolescents. Presented at the 153rd annual meeting of the American Psychiatric Association; May 13-18, 2000; Chicago, Ill
17. Welner Z, Reich W, Herjanic B, et al. Reliability, validity, and parent-child agreement studies of the Diagnostic Interview for Children and Adolescents (DICA). J Am Acad Child Adolesc Psychiatry 1987;26:649-653
18. Shaffer D, Fisher P, Dulcan MK, et al. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study: methods for the Epidemiology of Child and Adolescent Mental Disorders Study. J Am Acad Child Adolesc Psychiatry 1996;35: 865-877
19. Weller EB, Weller RA, Fristad MA, et al. Children's Interview for Psychiatric Syndromes. Washington, DC: American Psychiatric Press; 1999
20. Puig-Antich J, Chambers W. The Schedule for Affective Disorders and Schizophrenia for School-Age Children. New York: New York State Psychiatric Association; 1978
21. Luby JL, Belden A, Sullivan J, et al. Preschoolers' contribution to their diagnosis of depression and anxiety: uses and limitations of young child self-report of symptoms. Child Psychiatry and Hum Dev 2007;38:321-338
22. Kovacs M. Children's Depression Inventory Manual. North Tonawanda, NY: Multi-Health Systems; 1992
23. Kovacs M. The Children's Depression Inventory (CDI). Psychopharmacol Bull 1985;21:995-998
24. Beck JS, Beck AT, Jolly J. Manual for the Beck Youth Inventories of Emotional and Social Adjustment. San Antonio, TX: The Psychological Corporation; 2001
25. Reynolds WM. Adolescent Depression Scale: Professional Manual. Odessa, FL: Psychological Assessments Resources; 1987
26. Poznanski EO, Mokros HB. Children's Depression Rating Scale, Revised (CDRS-R) Manual. Los Angeles, CA: Western Psychological Services; 1996
27. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133: 429-435
28. Steingard RJ, Renshaw PF, Yurgelun-Todd D, et al. Structural abnormalities in brain magnetic resonance images of depressed children. J Am Acad Child Adolesc Psychiatry 1996;35:307-311
29. Steingard RJ, Renshaw PF, Yurgelun-Todd DA. Proton MRS and structural MRI of the orbitofrontal cortex of depressed adolescents. In: The 37th Annual Meeting of the American College of Neuropsychopharmacology; 1998; Las Croabas, Puerto Rico
30. Dahlstrom M, Ahonen A, Ebeling H, et al. Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents. Mol Psychiatry 2000;5:514-522
31. Ward S, Wisner KL. Collaborative management of women with bipolar disorder during pregnancy and postpartum: pharmacologic considerations. J Midwifery Womens Health 2007;52:3-13
32. Way CM. Safety of newer antidepressants in pregnancy. Pharmacotherapy 2007;27: 546-552
33. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007; 29:918-926
34. US Food and Drug Administration. Overview of Pregnancy and Lactation Subsection Content and Sample Labels. 2008. Available at: www.fda.gov/cder/ regulatory/ pregnancy_labeling/summary.htm. Accessed Sep 3, 2008
35. Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007;46:1503-1526
36. Centers for Disease Control and Prevention (CDC). Suicide trends among youths and young adults aged 10-24 years, United States, 1990-2004. 2007. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/ mm5635a2.htm. Accessed Sep 1, 2008
37. National Adolescent Health Information Center. 2006 Fact sheet on suicide: adolescents and young adults. Available at: www.nahic.ucsf.edu/ downloads/ Suicide.pdf. Accessed Sep 1, 2008
38. National Center for Injury Prevention and Control. Leading causes of death and fatal injuries: mortality reports (2006). Available at: www.cdc.gov/ncipc/wisqars/. Accessed Sep 1, 2008
39. Brent DA, Baugher M, Bridge J, et al. Age and sex-related risk factors for adolescent suicide. J Am Acad Child and Adolec Psychiatry 1999;38:1497-1505
40. Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. J Child Psychol and Psychiatry 2006;37: 372-394
41. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-1345
42. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-339
43. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007;164: 884-891
44. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297:1683-1696
45. March JS, Silva S, Petrycki S, et al. The Treatment of Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007;64:1132-1143
46. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebocontrolled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031-1037
47. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002;41:1205-1215
48. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-820
49. Wagner KD, Robb AS, Findling RL, et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004;161:1079-1083
50. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003;290:1033-1041
51. Emslie GJ, Bose A, Ventura D, et al. Escitalopram in the treatment of adolescent depression. Presented at the 161st annual meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC
52. Hughes CW, Emslie GJ, Crismon ML, et al. Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:667-686
53. Berard R, Fong R, Carpenter DJ, et al. An international, multicenter, placebocontrolled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2006;16:59-75
54. Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-772
55. Emslie GJ, Wagner KD, Kutcher S, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2006;45:709-719
56. Wagner KD, Jonas J, Findling RL, et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006;45:280-288
57. Organon Pharmaceuticals USA, Inc. A multi-center, randomized, double-blind, placebo-controlled, efficacy and safety study of Remeron in outpatient children and adolescents with major depressive disorder. 2001. Available at: www.clinicalstudyresults.org/ documents/company-study_51_0.pdf. Accessed Sep 5, 2008
58. Mosholder, AD, reviewer. Review and evaluation of clinical data. 2002. Available at: www.fda.gov/cder/foi/esum/2004/ 20152s032_Serzone_clinical_BPCA_FIN.pdf. Accessed Sep 5, 2008
59. von Knorring AL, Olsson GI, Thomsen PH, et al. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 2006;26:311-315
60. Emslie GJ, Findling RL, Yeung PP, et al. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2007;46:479-488
61. Emslie GJ, Ryan ND, Wagner KD. Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. J Clin Psychiatry 2005; 66(suppl 7):14-20
62. Weersing VR, Brent DA. Cognitive behavioral therapy for depression in youth. Child Adolesc Psychiatr Clin N Am 2006;15:939-957
63. Klomek AB, Mufson L. Interpersonal psychotherapy for depressed adolescents. Child Adolesc Psychiatr Clin N Am 2006; 15:959-975
64. Brent DA, Holder D, Kolko D, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry 1997;54:877-885
65. Rohde P, Clarke GN, Mace DE, et al. An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder. J Am Acad Child Adolesc Psychiatry 2004;43:660-668
66. Mufson L, Weissman MM, Moreau D, et al. Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 1999;56:573-579
67. Mufson L, Dorta KP, Wickramaratne P, et al. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 2004;61: 577-584
68. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull 2006;132:132-149
69. Watanabe N, Hunot V, Omori IM, et al. Psychotherapy for depression among children and adolescents: a systematic review. Acta Psychiatr Scand 2007;116:84-95
70. Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45:1404-1411
71. Vitiello B, Rohde P, Silva S, et al. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45:1419-1426
72. Curry J, Rohde P, Simons A, et al. Predictors and moderators of acute outcome in the Treatment for Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45:1427-1439
73. Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behavior therapy in adolescents with major depression: randomised controlled trial. BMJ 2007; 335:142-146
74. Melvin GA, Tonge BJ, King NJ, et al. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry 2006;45: 1151-1161
75. Byford S, Barrett B, Roberts C, et al. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioral therapy in adolescents with major depression. Br J Psychiatry 2007;191:521-527
76. Kennard BD, Emslie GJ, Mayes TL, et al. Relapse and recurrence in pediatric depression. Child Adolesc Psychiatr Clin N Am 2006;15:1057-1079
77. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48: 851-855
78. Rush AJ, Trivedi JH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917
79. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008;299:901-913
80. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder [Revision]. Am J Psychiatry 2000;157(suppl 4):1-45
81. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007;46:1503-1526
82. Cheung AH, Zuckerbrot A, Jensen PS, et al. Guidelines for adolescent depression in primary care (GLAD-PC), 2: treatment and ongoing management. Pediatrics 2006;120:e1313-e1326
83. Emslie GJ, Kennard BD, Mayes TL, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry 2008; 165:459-467
84. Cornwall P, Scott J. Partial remission in depressive disorders. Acta Psychiatr Scand 1997;95:265-271
85. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108
86. Keller MB. Remission versus response: the new gold standard of antidepressant care. J Clin Psychiatry 2004;65(suppl 4):53-59
87. Faravelli C, Ambonetti A, Pallanti S, et al. Depressive relapses and incomplete recovery from index episode. Am J Psychiatry 1986;143:888-891
88. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-1180
89. Simons A, Murphy G, Levine J, et al. Cognitive therapy and pharmacotherapy for depression: sustained improvement over one year. Arch Gen Psychiatry 1986;43:43-48
90. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavioral therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992;149:1046-1052
91. Cheung A, Kusumaker V, Kutcher S, et al. Maintenance study for adolescent depression. J Child Adolesc Psychopharmacol 2008;18:389-394